



Delcath Systems, Inc. to Participate at Upcoming Investor Conferences

May 26, 2010

NEW YORK, May 26, 2010 /PRNewswire via COMTEX/ --Delcath Systems, Inc. (Nasdaq: DCTH) announced today that it will present at the following upcoming investor conferences:

Jefferies 2010 Global Life Sciences Conference
Tuesday, June 8, 2010
New York, NY
4:30 p.m. ET
David McDonald, CFO of Delcath

9th Annual Needham Healthcare Conference
Wednesday, June 9, 2010
New York, NY
10:40 a.m. ET
David McDonald, CFO of Delcath

Management will review the company's business strategy and recent corporate developments. Delcath will offer live video webcasts of its presentations, which may be accessed on the Investor Relations section of the Company's website at <http://www.delcath.com/>. An archived replay of the presentations will be available for 30 days, also at <http://www.delcath.com/>.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at <http://www.delcath.com/>.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete the new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.